Use of GLP-1 analogue drugs is associated with benefits but also health risks
The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and obesity, may be associated with a wide range of health effects, both positive - such as a reduced risk of cardiometabolic disorders - and negative - an increased risk of gastrointestinal conditions or hypertension. These are the conclusions of an observational study published in Nature Medicine. The findings are based on analysis of data from 2.4 million participants.
0